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Tubulin cofactors (TBCs) participate in the folding, dimerization, and dissociation 
pathways of the tubulin dimer. Among them, TBCB and TBCE are two CAP-Gly 
domain-containing proteins that interact and dissociate the tubulin dimer. Here we show 
how TBCB localizes at spindle and midzone microtubules during mitosis. Furthermore, 
the motif DEI/M-COO– present in TBCB, which is similar to the EEY/F-COO– element 
characteristic of EB proteins, CLIP-170, and α-tubulin, is required for TBCE–TBCB 
heterodimer formation and thus for tubulin dimer dissociation. This motif is responsible 
for TBCB autoinhibition, and our analysis suggests that TBCB is a monomer in solution. 
Mutants of TBCB lacking this motif are derepressed and induce microtubule 
depolymerization through an interaction with EB1 associated to microtubule tips. TBCB 
is also able to bind to the chaperonin complex CCT containing α-tubulin, suggesting that 
it could escort tubulin to facilitate its folding and dimerization, recycling or degradation. 
 
Introduction 
The cytoskeleton of eukaryotic cells is required for many essential cell processes such as 
motility, organelle and membrane structural integrity, intracellular trafficking, 
chromosome segregation, and cytokinesis [1]. Microtubules are complex polar polymers 
of the cytoskeleton that assemble from αβ-tubulin heterodimers. The heterodimers 
polymerize, forming protofilaments that associate laterally, forming the wall of a hollow 
cylinder, the microtubule[2,3]. Therefore, within the microtubule lattice, each single α-
tubulin or β-tubulin subunit interacts with four other neighboring tubulin subunits. In 
fact, each α-tubulin subunit interacts with its β-tubulin partner inside of the heterodimer, 
with a second β-tubulin subunit from the preceding heterodimer in the protofilament, and 
laterally with two α-subunits from the two side protofilaments. Thus, the assembly of a 
microtubule, while preventing unwanted interactions, is a highly complex task that must 
be properly controlled to avoid critical errors. 
Tubulin folding cofactors (TBCs) are a set of different proteins discovered a decade ago 
in the so-called "postchaperonin" tubulin folding pathway. TBCs are responsible for the 
achievement of the quaternary conformation of the αβ-heterodimer after tubulin 
monomers have reached their tertiary structure [4,5]. More recent studies have shown that 
in vivo, these proteins are implicated in microtubule dynamics through their ability to 
dissociate the tubulin heterodimer, and probably by controlling tubulin monomer quality 
and exchange (shuffling mechanism) [6-8]. 
TBCB and TBCE are two well-conserved α-tubulin interacting proteins that collaborate 
in the regulation of microtubule dynamics [6-9]. Both cofactors participate in the α-
tubulin folding pathway and are required for cell survival [5, 10], playing important roles 
in vivo as revealed by the plethora of human disorders in which they are implicated. 
TBCE mutations cause a syndrome called hypoparathyroidism-retardation-dysmorphism, 
also known as the Sanjad–Sakati syndrome [11] in humans, and a progressive motor 




































































cancer [13], neurodevelopmental malformations [14], schizophrenia [15], and 
neurodegenerative processes [16]. 
TBCB shares with TBCE two similar domains, a CAP-Gly domain at the N-terminus, 
and a UBL domain at the C-terminus, but while TBCB it is not able to interact with or 
dissociate the tubulin heterodimer by itself, TBCE is, per se, effective in promoting this 
dissociation. Nonetheless, TBCE interacts with TBCB, originating the TBCE–TBCB 
complex, which displays a more efficient stoichiometric tubulin dissociation activity than 
TBCE alone. Upon dissociation, TBCB, TBCE, and α-tubulin form a stable ternary 
complex. The disassembly of this ternary complex results in either TBCB and α-tubulin, 
and free TBCE, or TBCE and α-tubulin, and free TBCB. Free β-tubulin subunits might 
be recyclable in the presence of TBCA or TBCD [9]. 
The function of the CAP-Gly domains of both cofactors is still unknown. This domain is 
a protein-interaction module that typically plays a role controlling microtubule end 
dynamics in end-binding proteins (EBs), which can track along microtubule ends [17-19]. 
In addition to EBs, an increasing number of proteins that control microtubule 
organization and dynamics, known as microtubule plus-end-tracking proteins (+TIPs), 
have been identified. These proteins connect to the microtubule plus ends through an 
interaction with members of the EB family [17-19], the only known protein family that 
can track microtubule ends autonomously. Recently, a long list of +TIPs candidates has 
been published by Yu et al. (2011) [20], but neither TBCB nor TBCE has been included. 
In this work, we have used a multidisciplinary approach to study the molecular 
mechanism of TBCB's regulation of microtubule dynamics. For this purpose, we have 
cloned the human Tbcb gene and characterized mutant versions of its product, having 
established that the last three amino-acid residues of this protein are crucial for TBCB 
autoinhibition. In fact, the overexpression of the mutated form of TBCB lacking the 
DEI/M-COO– motif, similar to the EEY/F-COO– element in EB1 and related proteins, 
produces a massive microtubule destruction in vivo. Using extensive biophysical and 
biochemical approaches, we unmasked the molecular mechanism by which TBCB 
controls microtubule depolymerization by means of EB1. In addition, we show for the 
first time that TBCB interacts directly with cytosolic chaperonin containing TCP-1 
(CCT) during the folding process of α-tubulin. All the results obtained from this work led 
us to propose three different models to explain the autoinhibition of TBCB, its role in 
tubulin folding as a CCT cofactor, and the mechanism by which the deregulation of 
TBCB activity induces the microtubule catastrophe in living cells. 
 
Materials and Methods 
Human TBCB gene cloning  
The human tbcb coding sequence was amplified by PCR from a testis cDNA sample (BD 
Biosciences, USA) using a pair of primers designed with the appropriate restriction 
enzyme recognition sites at their ends: forward primer 5′ GTG AAG CTT CAT ATG 




































































CAA CCC 3′. The amplified coding sequence was then inserted in the HindIII and 
BamHI sites of the mammalian expression vector pcDNA3.1 (Invitrogen, Life 
Technologies, USA) to generate the pcDNA3.1-TBCB recombinant plasmid. Human 
TBCB was cloned into the pEYFP vector from Clontech (Clontech Laboratories, USA). 
TBCB∆3 and TBCB∆9 cDNA fragments were produced by PCR. The resulting 
fragments were cloned into pET29c and sequenced (EMD Millipore Bioscience 
Novagen, USA). 
TBCA and TBCE protein purification and characterization 
Human TBCE cDNA wild-type (accession number U61232) and human TBCA [21] were 
His-tagged at the C-terminus and cloned into the pRJ-pFastBac vector [8] for 
recombinant baculovirus production using the Bac-to-Bac Baculovirus Expression 
System (Invitrogen, Life Technologies, USA). These were then used to infect 
commercially obtained Sf9 insect cells to produce recombinant TBCE, which was 
purified following protocols already described elsewhere with minor modifications [8,9]. 
TBCAHis was purified from a 50 mL culture of Sf9 cells infected with baculoviruses 
carrying the human TBCAHis cDNA cloned. Cells were pelleted by centrifugation, 
washed, and stored frozen at –70°C. Pellets were resuspended in 7.5 mL of 0.5 mM Tris 
buffer (pH 8) containing protease inhibitors and sonicated three times during 20 seconds 
at 4°C. Extract was spun at 60,000 ×g in a Ti 50.2 ultracentrifuge rotor (Beckman-
Coulter) for 30 min at 4°C. Supernatant was supplemented with a buffer stock to produce 
final concentrations of 50 mM Tris-buffer (pH 8) and 500 mM NaCl and 10 mM 
imidazole and loaded into a 1 mL His-Trap column (GE Healthcare). Fractions 
containing TBCA–His were pooled and concentrated by ultrafiltration using an Amicon 
Ultra 10K filter (Millipore, USA). Protein concentrate was applied to a high-resolution 
gel-filtration column (Superdex-75 HR, GE Healthcare, USA), equilibrated and eluted 
with 20 mM Bis-Tris buffer (pH 7) containing 100 mM KCl, 1 mM DTT and 0.5 mM 
PMSF at 0.4 mL/min. 
Nonclassical two-dimensional electrophoresis 
In the first dimension, the protein complexes were fractionated by charge and shape, and 
then were denatured and their molecular composition determined in the second 
dimension. The samples were loaded onto a native 0.75 mm thick minigel (7 cm × 8 cm) 
as described [22, 23]. After two hours of electrophoresis, a single running lane containing 
the native electrophoresed sample was excised with a blade on glass, loaded onto a 
preparative 1.5 mm thick SDS-minigel (7 cm × 8 cm), and fixed to the gel with 0.5% 
agarose prepared in 1× SDS loading buffer. Denaturing electrophoresis was performed 
for three hours at 10 mA constant current, after which the gel was stained with 
Coomassie Blue G-250. In a similar manner, bands of interest were excised with a blade 
on glass, dried in a Speed-Vac concentrator (Thermo Fisher Scientific, USA) and 
rehydrated with loading 1× SDS loading buffer, heated at 90°C for 2 min, and loaded 




































































Antisera production, immunocytochemistry, and cell cultures 
Affinity-purified primary antibodies were produced against purified human TBCB 
recombinant protein. Rabbit sera were affinity purified as described previously [24]. For 
immunocytochemistry, the antibodies used were anti-α- and anti-β-tubulin (B512 and 
Tub2.1, respectively) and anti-acetylated tubulin from Sigma-Aldrich. The anti-
glutamylated tubulin antibody (GT335) was a gift from Dr. Janke (CNRS, Montpellier, 
France). Secondary antibodies were Alexa-Fluor-488-conjugated goat anti-rabbit IgG and 
goat-anti-mouse IgG, Alexa-Fluor-647-conjugated goat anti-mouse IgG (Molecular 
Probes, Invitrogen), Cy3-conjugated goat anti-mouse IgG and goat anti-mouse IgG1, and 
Cy5-conjugated goat anti-rabbit IgG (Jackson ImmunoResearch Laboratories). For some 
experiments, microtubules were depolymerized with 2 µM nocodazole and cold (4°C) 
treatments for 30 min. 
Microtubule depolymerization experiments 
Bovine brain tubulin was purified as described [25]. Purified tubulin was incubated at 
35°C for 20 minutes, and as a control, TBCB or ovalbumin was added for another 20 
minutes in buffer A (MES 100 mM pH 6.7, EGTA 1 mM, and MgCl2 1 mM) with 2 mM 
GTP and 30% glycerol. The pellet and supernatant were separated after centrifugation at 
45,000 ×g for 1 hour at 30°C through a 50% sucrose cushion containing 1 mM GTP. 
Fractionation by gel filtration of complexes formed between cofactors TBCB and 
TBCE and TBCB 
Purified tubulin cofactors and complexes formed in reactions conducted at 30°C for 30 
minutes were fractionated in a Superdex 200 PC 3.2/30 gel-filtration precision column 
using an Ettan LC (GE Healthcare) at room temperature. The elution buffer contained 0.1 
M MES (pH 6.7), 1 mM MgCl2, 1 mM EGTA, and 25 mM KCl. Fractions of 25 µL were 
eluted at 40 µL/min and were analyzed by SDS–PAGE. 
Confocal microscopy, cell counts, and statistical analysis 
Transitory transfection experiments were performed using Lipofectamine Plus reagent 
(Life Technologies) or the FuGene 6 reagent (Roche) following the manufacturer's 
instructions. The GFP:EB1 construct was kindly supplied by Dr. Akhmanova (Utrecht 
University, The Netherlands). Cell counts in Figure 1C were performed at 30 h post 
transfection using a 63× Zeiss oil immersion objective starting from a random field and 
scanning horizontally from that point. Values presented in the histogram of Figure 1C 
were obtained by double immunofluorescence with anti-α-tubulin/TBCB. Values in 
Figure 5D were obtained by double immunofluorescence with anti-α-tubulin/TBCB 
combined with Hoechst 33258 and GFP labeling in cotransfection experiments. Cell 
counts were performed on confocal microscopy projection images using a Nikon A1R 
LSM confocal microscope equipped with an argon (488 nm) laser, two HeNe (564 and 




































































presented healthy-looking nuclei, as assessed by Hoechst staining, were considered. In 
colocalization experiments, images were scanned sequentially to avoid fluorescent 
channel emission cross talk / bleed through. A t test was performed on data obtained from 
two different coverslips of at least three different experiments. Statistical analysis of data 
and graphing were performed using SigmaPlot 8.0 software (Systat Software, Richmond, 
CA). Histograms represent mean values and standard error bars. 
Tubulin dimer dissociating assay and nondenaturing electrophoresis 
Aliquots of purified brain tubulin were mixed with different amounts of purified TBCE in 
15 µL reactions containing 50 mM MES (pH 6.7), 1 mM MgCl2, and 1 mM GTP in the 
absence and presence of a stoichiometric excess of TBCB or TBCB∆3, and incubated for 
30 min at 30°C. The reaction mixtures were diluted with a sucrose-containing native 
loading buffer and loaded onto a 6% nondenaturing polyacrylamide gel [22, 23]. Native 
gels were stained directly with Coomassie Brilliant Blue. 
Affinity chromatography 
Purified TBCB∆3 was coupled specifically at its amino terminus using EDC-NHS 
coupling chemistry in a Hi-trap NHS-activated HP column (GE Healthcare). This column 
gave us complete control over the experimental conditions (extract preparation, column 
loading, bound partner elution, time, and temperature). Thus, HEK293 cell extracts were 
prepared, sonicated to fragment microtubules, and loaded into the column at 4°C, to 
avoid protein degradation. We used a slow loading rate, to allow binding of the 
interactors to the column. 300 mg of HEK293 were resuspended and subject to a 
hypotonic shock in Tris buffer 20 mM (pH 7.3) and PMSF 0.5 mM (buffer H). 
Subsequently, cells were sonicated three times during 30 s at 130 watts at 4°C. Protein 
extract (1 mL at 18 mg/mL) obtained from human HEK293 cells was applied to the NHS 
column equilibrated in buffer H. The column was washed with 10 mL of the same buffer, 
and specifically interacting proteins (detail) were eluted with a NaCl gradient (red line). 
Results 
Auto-inhibition of TBCB 
TBCB is encoded by a unique gene in the human genome. This protein is composed of 
two functional structural domains connected by a coiled-coil segment (Fig 1A). At the N-
terminus, TBCB contains a ubiquitin-like domain. This domain is spherical (PDB ID, 
1V6E), behaves as a monomer of about 14 kDa and is a ubiquitous protein interaction 
domain present in many unrelated proteins. The C-terminal domain is a CAP-Gly 
characteristic of +TIPs proteins. This domain is also globular, with a three-layer β–β 
structure (three antiparallel β-sheets), as represented by the C. elegans F53f4.3 protein 
CAP-Gly domain (Fig 1A, PDB: 1TOV, [26]). The unique α-helix is preceded by a 
disordered stretch of 17 residues, and the last 6–7 amino acid residues protrude from the 




































































peptides [27]. This sequence assumes an extended conformation, and the side chain of the 
terminal tyrosine packs with several hydrophobic amino acid residues in the CAP-Gly 
domain [28]. The crystal structure of the CAP-Gly of TBCB (C. elegans) revealed that 
this domain consists of 84 amino acid residues, and although it does not form a dimer in 
vitro, the conserved groove, involved in the interaction with EEY/F-COO– elements 
characteristic of EB, CLIP-170, and α-tubulin, holds the C-terminal peptide of the 
neighboring molecule in the asymmetric unit of the crystal [26]. 
The structural prediction [29] for the human TBCB's last nine amino acid residues (Fig 
1a) is that of a disordered peptide, protruding from the globular domain and thus being 
able to interact with a CAP-Gly domain groove. Indeed, theoretical models [28, 30] have 
shown putative interactions between the p150Glued CAP-Gly domain and the C-terminal 
peptide of EB1 and TBCB. 
Taking into account the structural features of the TBCB C-terminal domain, we decided 
to go further in understanding the TBCB and TBCB C-terminus interaction and to 
determine whether the C-terminal region would also affect the tubulin binding ability of 
TBCB. These ideas led us to propose the hypothesis of an autoinhibitory mechanism 
where the TBCB C-terminal extension folds over the globular part of its own CAP-Gly 
domain and structurally blocks the conserved groove involved in the interaction with 
EEY/F-COO– elements characteristic of EBs, CLIP-170, and α-tubulin. For this purpose, 
we have cloned the human Tbcb gene and constructed two Tbcb mutants lacking the last 
three (TBCB∆3) and last nine (TBCB∆9) amino acid residues, predicted to be 
unstructured. These truncated proteins were overexpressed in HeLa cells and visualized 
using new polyclonal anti-TBCB antibodies (see Material and Methods). 
Previously, we showed that the overexpression of either TBCE or TBCD in human cell 
lines leads to the sequestration of free α- and β-tubulin respectively, leading to massive 
microtubule depolymerization [6-8]. On the other hand, murine TBCB overexpression 
only leads to a moderate microtubule depolymerization effect, probably because of the 
limiting concentrations under TBCB overexpression conditions, of endogenous TBCE 
required for the binding and dissociation of the tubulin heterodimer [9]. 
Unpredictably, overexpression of the TBCB∆3 mutant in HeLa cells induced a massive 
microtubule destruction effect, comparable only to that observed upon TBCE 
overexpression (Fig 1b; [9]). Quantification of the microtubule destruction effect 
revealed that at 30 h post transfection, over 60% of the TBCB∆3 positive cells exhibited 
no detectable microtubules, while only less than 20% of the overexpressing cells had an 
apparently unaffected microtubular cytoskeleton. Similar results were obtained for the 
TBCB∆9 mutant. These findings strongly support the proposed idea that TBCB is self-
inhibited by its C-terminus and that the removal of only the last three amino-acid residues 
from this domain is sufficient to activate TBCB. 
These results prompted us to investigate whether TBCB∆3 was able to depolymerize 
microtubules assembled in vitro. For this purpose, we purified brain tubulin and the 
untagged TBCB∆9 and TBCB∆3 proteins (Fig S1a). Stoichiometric amounts of purified 
TBCB∆3 or ovalbumin (negative control) were incubated with GTP and polymerized 
purified tubulin. The incubation mix was then centrifuged, and both the soluble and 




































































TBCB∆3 proteins in the two fractions (Fig S1b). These experiments revealed that 
TBCB∆3 was essentially present in the supernatant fractions. Moreover, similar amounts 
of tubulin were found in the supernatant and pellet fractions in the presence or absence of 
TBCB∆3, which were also similar to those found when ovalbumin was used (Fig S1b). 
These results lead to the conclusion that TBCB∆3 is not able to depolymerize 
microtubules in vitro, presumably because of the lack of a factor mediating its in vivo 
effect. 
The proposed model for TBCB’s autoinhibition implies the interaction of the C-terminal 
tail of this cofactor with its own CAP-Gly domain. To test this hypothesis, we performed 
quantitative binding assays by using fluorescence polarization of fluorescein labeled 
peptides (Table 1; see also Supplementary Material and Supplementary Table 1). The 
equilibrium dissociation constants show that the C-terminal nonapeptide (peptide 1) 
presents a higher affinity for TBCB (12 µM) than that displayed by the same peptide 
lacking the last three residues (peptide 2), which was six times lower. Similarly, the C-
terminal deleted proteins TBCB∆3 and TBCB∆9 showed a sixfold reduction in the 
affinity for the complete C-terminal peptide of TBCB (peptide 1). Besides, the binding 
affinities exhibited by the C-terminal deleted peptide 2 for the deleted TBCB forms are 
significantly lower than for the full-length protein. Together these results strongly support 
the idea that the last three amino acid residues of the TBCB C-terminus are involved in 
the binding to TBCB, thus reinforcing our model of TBCB autoinhibition. 
Finally, CAP-Gly domains have a high affinity for the C-terminal tail of α-tubulin (i.e., 
CLIP-170 CAP-Gly domain 2; [31]). In order to corroborate our model, we have also 
quantified the binding affinity of TBCB to two different α-tubulin peptides (Tables 1 and 
S1; peptide 3 and peptide 4). We designed a peptide (GEGEEEGEEY) corresponding to 
the C-terminus of α-tubulin isotypes 1 and 2, containing the last tyrosine residue, known 
to be critical for binding to CAP-Gly domains [31]. As expected, all three polypeptides 
(TBCB, TBCB∆3, and TBCB∆9) displayed a KD value higher than that exhibited by the 
TBCB-peptide (EEDYGLDEI). In the case of wild-type TBCB and α-tubulin 
(GEGEEEGEEY), the KD is about four times higher (43 µM) than that obtained for the 
TBCB peptide (EEDYGLDEI). 
Altogether, the results indicate that TBCB does not interact with tubulin dimers and 
demonstrate that the TBCB CAP-Gly domain is functionally different from other CAP-
Gly domains. Finally, they confirm that TBCB is autoinhibited by the last three amino 
acid residues of its C-terminus. 
The C-terminal acidic tail of TBCB is responsible for TBCE interaction 
Previous work from our group has shown that when incubated together, purified 
mammalian TBCB and TBCE produce a new peak in gel filtration analysis 
chromatograms that correspond approximately to the sum of the molecular masses of 
individual TBCB and TBCE [9]. Further analysis of this peak revealed the presence of 
both cofactors suggesting that purified TBCB forms a binary complex with TBCE ([9] 
and Fig 2a, left panel). Bearing in mind these results and that the last three amino acid 




































































whether the TBCB∆3 or TBCB∆9 truncated proteins are also able to dimerize with 
TBCE. Interestingly, when purified TBCE is incubated with purified TBCB∆3 (Fig 2a, 
right panel) no additional peaks are detected in gel filtration chromatograms. Indeed, 
chromatograms only revealed peaks corresponding to the species present when the single 
purified proteins were analyzed. This observation was confirmed by SDS-PAGE analysis 
of the corresponding fractions (Fig 2a). These results strongly suggest that none of the 
TBCB C-terminus deleted mutants is able to interact with TBCE and that the last three 
amino acid residues of TBCB are essential for the TBCE recognition. 
TBCE and TBCB, the tubulin heterodimer dissociation machine 
Because the TBCE and TBCB interaction is required for an efficient tubulin heterodimer 
dissociation activity, the results above predict that the last three amino acid residues of 
TBCB are also critical for this process. Therefore, we have investigated the tubulin 
heterodimer dissociation activity of TBCE in the presence of either full-length TBCB or 
TBCB∆3 and have quantified the different molecular species produced by native-PAGE. 
When tubulin heterodimers are incubated with TBCE in the presence of TBCB, an extra 
band (Fig 2b), which probably corresponds to the ternary complex composed of TBCB, 
TBCE, and α-tubulin, is detected in native gels. To confirm the composition of this band 
(Fig 2b, second dimension), we have analyzed the sample where TBCE was incubated 
with TBCB and α-tubulin using a nonclassical two-dimensional PAGE method [23]. 
Thus the incubation sample was analyzed in a native gel for the first dimension (Fig 2b). 
Then, to resolve the complex’s composition, the respective lane of the native gel was 
directly applied into a denaturing gel for the second dimension. This analysis confirmed 
that the new extra band corresponds to the ternary complex (Fig 2b and 2d). Interestingly, 
in similar incubations where TBCB was replaced by TBCB∆3, the ternary complex is 
absent, and instead an extra band that migrates a little bit less than that corresponding to 
tubulin heterodimers was found. To determine the molecular composition of this new 
band, we performed a second-dimension analysis similar to that described above (Fig 2c 
and 2d). This analysis showed that this band corresponds to the binary complex 
containing α-tubulin and TBCB∆3. Therefore, TBCB∆3 is able to interact with α-tubulin 
but not with TBCE. 
TBCE and TBCD were characterized as the tubulin cofactors that are able to dissociate 
the tubulin heterodimer [6-8]. Although it was stated that TBCB cannot dissociate the 
tubulin heterodimer, we decided to investigate whether TBCB or TBCB∆3 or both also 
have this ability. For this purpose, we decided to repeat the dissociation experiments by 
performing them in the presence of TBCA to improve the visualization of the tubulin 
heterodimer dissociation. It was previously shown that this cofactor, capturing the β-
tubulin subunits emerging from tubulin dimers dissociated by TBCE, forms a binary 
complex detectable in native gels [8]. As observed in Fig 2d, when tubulin heterodimers 
are incubated with TBCE in the presence of TBCB and TBCA, dissociation is complete, 
forming the ternary complex (TBCB, TBCE, and α-tubulin) described above, which 
comigrates with TBCA and the binary TBCA and β-tubulin complex. On the other hand, 




































































ternary complex is not detected, but binary complexes containing TBCB∆3 and α-
tubulin, and TBCA and β-tubulin are clearly visible. In contrast, neither TBCB nor 
TBCB∆3 by itself gives rise to the formation of TBCA and β-tubulin complexes, 
demonstrating that they do not have the ability to dissociate the tubulin heterodimer in the 
absence of TBCE (Fig 2d). 
To understand better the role of these cofactors in tubulin heterodimer disruption, we 
decided to perform a time course of the dissociation activities of TBCE alone and in the 
presence of stoichiometric amounts of TBCB or TBCB∆3. We observed that while TBCE 
alone dissociates 60% of the tubulin heterodimers in 30 minutes (Fig 2e), TBCE in the 
presence of TBCB is able to dissociate about 90% in less than 30 seconds (the minimal 
time required to mix the incubation components and load it into the gel). In contrast, in 
the same period, but in the presence of TBCB∆3, only 25% of tubulin heterodimers are 
dissociated by TBCE. Although in the presence of TBCE there is a clear difference 
between the dissociating activities of the TBCB and the TBCB∆3 (90% to 25%), the 
small increase in the dissociation activity percentage in the presence of TBCB∆3 
compared with that observed for TBCE alone (9%) might be because TBCB∆3 can form 
a binary complex with α-tubulin that would facilitate the dissociation activity of TBCE 
(Fig 2f and 2g). 
Together, our data clearly show that the last three residues in TBCB are not required for 
the formation of the binary complex with α-tubulin. However, they are not only 
implicated in TBCB autoinhibition but also essential for the interaction of TBCB with 
TBCE and therefore required for the assembly of an efficient tubulin heterodimer 
dissociation machine. 
Moreover, based on these results, we put forward the hypothesis that TBCE would 
interact with the C-terminus of TBCB, which would lead to the derepression of this 
cofactor triggering a microtubule catastrophe. However, the observation that neither 
TBCB∆3 nor TBCB∆9 (results not shown) is able to interact with TBCE is still puzzling 
because their overexpression resulted in massive microtubule depolymerization in HeLa 
cells (see Fig 1b and 1c). 
In solution, TBCB is a monomer as revealed by biophysical studies and cross-
linking experiments 
The possible TBCB autoinhibition is supported by the interaction observed between the 
C-terminal peptide molecules in the crystal structure of the CAP-Gly domain of C. 
elegans TBCB [26]. To obtain clues regarding the behavior of native TBCB that could 
help us to elucidate the molecular mechanism underlying its autorepressed activity, we 
used different experimental approaches to investigate whether TBCB is a monomer or a 
dimer in solution. For this purpose, we first determined the circular dichroism (CD) 
spectra of the TBCB, TBCB∆3, and TBCB∆9 proteins (Supplementary Material). The 
CD spectra of the three proteins (Fig S2a, left panels) was characterized by the presence 
of two minima at 208 and 217 nm, which are indicative of a mixed population of α-
helical (20%, [θ]222/208 = 0.87) and β-strand (30%) conformations. The absence of a 




































































helices and β-strands) suggest the additional presence of disordered (random coils and 
turns) structures (50%). 
Subsequently, we decided to study the state of aggregation of these proteins by dynamic 
light scattering, but obtained inconclusive results (DLS, [32]; see Supplementary 
Material). By using a gel filtration analysis, we have previously characterized the 
molecular components of the different complexes formed between TBCB, TBCE, and 
tubulin [9]. Based on the elution volumes, the estimated molecular mass of TBCB was 
30%–40% larger (40 kDa) than that predicted from its amino acid sequence (27 kDa). 
Curiously, this value for TBCB coincided with the molecular mass estimated from its 
mobility on SDS-PAGE. However, the apparent molecular mass of the complexes formed 
between TBCB and TBCE, and between TBCB and TBCE and α-tubulin, suggested that 
they were the result of the sum of the molecular masses of the monomeric subunits. 
These apparent discrepancies in the values of TBCB molecular masses were maintained 
upon DLS estimations of the molecular mass of TBCB (69 kDa), TBCB∆3 (53 kDa), and 
TBCB∆9 (34 kDa; Fig S2b). In order to clarify these observations, we decided to 
investigate the state of oligomerization of the three proteins by cross-linking experiments 
(Fig 3a) and analytical ultracentrifugation (Fig 3b). We used glutaraldehyde as a general 
protein cross-linker and a protein (EB1) with a very low KD for dimer formation, as a 
positive control. Interestingly, the results revealed that purified TBCB, as well as 
TBCB∆3, migrates in SDS-PAGE as a single band with an apparent molecular mass of 
about 38–40 kDa. Nevertheless, when these two proteins are incubated with 
glutaraldehyde (0.05%), the band corresponding to 40 kDa, although still visible in trace 
amounts, is substituted by a new band corresponding to species with a molecular mass of 
about 27 kDa (Fig 3a). This molecular mass is in agreement with the theoretical 
molecular mass of these two proteins. On the other hand, the EB1 control protein, which 
normally migrates as a single band of 32–34 kDa after glutaraldehyde treatment, migrates 
as a band of 64 kDa, which is consistent with its size in gel filtration experiments (Fig 
S2d). These results were confirmed by an analytical ultracentrifugation analysis that was 
performed at 20°C at 160,000 ×g (Fig 3b). Indeed, the analytical ultracentrifugation 
showed that the molecular mass of TBCB was ~25.5 kDa, corresponding to the size of 
the monomer (27 kDa). Taken together, all these results led us to conclude that TBCB 
behaves as a monomer and to suggest that its self-inhibition occurs within the same 
molecule and not between two or more TBCB molecules. 
TBCB localizes to the centrosome and mitotic spindle microtubules 
TBCB has been shown to colocalize with Pak1 protein on newly polymerized 
microtubules [13]. Because the overexpression of TBCB and TBCB∆3 leads to 
microtubule depolymerization, we decided to investigate the subcellular distribution of 
the overexpressed YFP:TBCB protein in HeLa cells throughout the cell cycle. 
As observed for the wild-type endogenous protein [9], YFP:TBCB is mostly a soluble 
cytoplasmic protein in interphase cells (Fig 4a). A prominent spot of YFP:TBCB is often 
localized at the centrosome (double spot) and at the base of the primary cilium (Fig 4B). 
Indeed, the distribution of YFP:TBCB during mitosis revealed two clear YFP:TBCB 




































































metaphase, TBCB was also localized to spindle microtubules (Fig 4a, top right). This 
localization was also observed for overexpressed wild-type untagged TBCB by 
immunostaining  and is in accordance with previous analyses performed for endogenous 
TBCB in human and mouse cells [9,13,33]. Furthermore, with this new analysis, we 
observed that during anaphase A, YFP:TBCB becomes more visible as thin filaments 
bridging the midzone, and by anaphase B most of this cofactor had progressively 
disappeared from the centrosome and was concentrated on the midbody microtubules 
(Fig 4a, bottom). At the end of telophase, TBCB was apparently absent from the 
centrosome, concentrating in a unique spot at the midbody. These localization results 
show evidence that TBCB can bind to microtubules. However, we know from all the 
results described above that TBCB cannot recognize tubulin heterodimers, suggesting 
this binding to be indirect, occurring through the interaction of TBCB with a microtubule 
binding protein. 
TBCB∆3 interacts with EB1 and the cytosolic chaperonin CCT 
That in vivo TBCB is able to localize at mitotic spindle microtubules and to promote 
microtubule destabilization, whereas in vitro it is not able to depolymerize or even to 
interact with microtubules, strongly suggests that in vivo TBCB should have an 
interactor(s) that mediates its functions toward microtubules. This prompted us to search 
for TBCB molecular interactors. In a first approach, we have performed different 
experiments such as yeast two-hybrid and immunoprecipitation techniques, but we were 
unsuccessful in the identification of any TBCB interactor. This could be ascribed to the 
fact that we have not used specific conditions required to avoid disruption of weak 
interactions. To overcome these problems, we constructed an affinity column with bound 
recombinant untagged TBCB∆3, the derepressed version of TBCB. Bound proteins or 
complexes were specifically eluted with a salt gradient that produced a double peak 
between 100 and 200 mM NaCl, and the corresponding fractions were analyzed by SDS-
PAGE. 
The different bands (Nos. 1–6, Fig 5b) detected in SDS-PAGE gels were subjected to 
trypsin digestion followed by mass fingerprinting analysis. Notably, this analysis 
revealed that band No. 1 corresponds to human EB1. The sequence coverage was 83% 
corresponding to MARE 1 (UniProt accession C1BKD9, Fig S3A). The analysis showed 
that band Nos. 3–5 correspond to the eight distinct human CCT subunits required to 
assemble CCT completely. All the CCT-subunits were identified with a sequence 
coverage higher than 45%, and for most of the cases, the coverage was about 70% (Fig 
S4a). The presence of complete CCT hetero-oligomeric particles in the eluted fractions 
was also confirmed by conventional electron microscopy. Notably, CCT is a group II 
chaperonin mostly committed to the folding of actins and monomeric α- and β-tubulin 
[34]. Therefore, this is the first evidence demonstrating that a tubulin folding cofactor is 
able to bind directly to CCT, an interaction that may be relevant for the tubulin folding 
process. 
In addition to these interactors, we also found that band No. 2 corresponds to α- and β-
tubulin (Fig 5b). In fact, five α-tubulin isotypes and seven β-tubulin isotypes (Fig S4b) 




































































and generally with a value of about 50%–60% (Fig S4b).These results also show that the 
HEK293 cell line expresses all known tubulin isotypes. Because TBCB∆3 does not bind 
tubulin heterodimers or microtubules in vitro and only binds to α-tubulin, but not to β-
tubulin monomers, these results strongly suggest that TBCB∆3 would bind microtubules 
through a partner and that this partner must be EB1. 
EB1 overexpression prevents TBCB∆3 microtubule destruction 
The finding that EB1 is a TBCB interactor makes this protein the most attractive 
candidate for explaining how TBCB is able to regulate microtubule dynamics. Because 
EB1 is known to stabilize the plus ends of microtubules, its interaction with TBCB would 
explain how TBCB is able to promote a microtubule catastrophe when overexpressed. In 
this context, we may expect that TBCB has the ability to sequester EB1 from microtubule 
plus ends. If these hypotheses were true, the overexpression of EB1 would be sufficient 
to rescue the observed phenotype of microtubule depolymerization when TBCB and 
TBCB∆3 are overexpressed. This would also provide evidence of the interaction of EB1 
with TBCB in vivo. To examine this model, we have cotransfected HeLa cells with wild-
type TBCB and GFP:EB1 or TBCB∆3 and GFP:EB1. As predicted, the obtained results 
show that microtubule destruction resulting from simultaneous overexpression of 
TBCB∆3 + GFP:EB1 or TBCB and GFP:EB1 was substantially less accentuated than 
that observed in cells only overexpressing TBCB∆3 or TBCB, respectively (Fig 6a). We 
also observed that the typical GFP:EB1 comets, resulting in the localization of this 
protein at growing microtubule plus ends, were no longer observable (Fig 6a, bottom), 
suggesting that excess TBCB∆3 was interacting with EB1 modifying its intracellular 
distribution. 
To confirm further whether TBCB∆3 interacts with EB1 in this system, we next 
quantified and compared the microtubule destruction effect at specific time points against 
the background of overexpressing GFP:EB1+TBCB∆3 versus overexpressing 
GFP:EB1+TBCB. Therefore, cotransfected cells and controls were fixed at different time 
points. Triple labeling experiments revealed that 10 times as many cells preserved their 
microtubule cytoskeleton when cotransfected with both genes (Fig 6b). Hence, this 
system suggests that the TBCB∆3 depolymerization effect is virtually blocked by 
overexpressed EB1 and thus confirms that TBCB∆3 and EB1 interact in vivo. 
 
Discussion 
In this work, we found that the TBCB CAP-Gly domain is autoinhibited by interaction 
with the last three residues of its C-terminus. Our data also show that these last three 
residues of TBCB are required for TBCE recognition, interaction and tubulin heterodimer 
dissociation. Therefore, we have proposed a molecular mechanism explaining how TBCB 
and TBCE form a binary complex that efficiently recognizes and dissociates the tubulin 
heterodimer. 
Biophysical studies revealed that a TBCB protein lacking the last three amino acid 




































































response to unfolding by heat. Cross-linking experiments and analytical 
ultracentrifugation, in contrast to dynamic light scattering, show that TBCB behaves as a 
monomer of 25.5 kDa. The TBCB∆9 protein, which lacks the last nine amino acid 
residues, presents a similar CD spectrum and the same unfolding temperature as TBCB 
and TBCB∆3. This truncated version of the TBCB protein shows a completely different 
behavior under heat denaturing conditions, but the values from the dynamic light 
scattering also suggest that it is a monomer (Fig S2). When overexpressed in human cells, 
TBCB is able to induce microtubule loss [9]. Although initially this could be ascribable 
to its interaction with endogenous TBCE, we found that the mutant lacking the last three 
amino acid residues and unable to interact with TBCE depolymerizes microtubules in 
vivo with a higher efficiency. This suggests that the C-terminal region is an 
autoinhibitory sequence and that the mechanism of microtubule depolymerization by 
TBCB∆3 is TBCE independent (Fig 7a). Microtubule destruction was accompanied by an 
intense tubulin background in the cells when detected with both anti-α- and anti-β-
tubulin antibodies, suggesting the presence of soluble tubulin heterodimers in the cytosol 
of the cells. This cytoplasmic background is very unusual in TBCE or TBCD 
overexpressing cells where these two cofactors sequester either α- or β-tubulin 
respectively upon tubulin heterodimer dissociation, which leads to microtubule 
depolymerization and microtubule network collapse. 
To gain insights into the mechanism by which TBCB causes microtubule 
depolymerization, we have studied whether or not TBCB was able to depolymerize 
microtubules assembled in vitro. We demonstrated that TBCB was not a microtubule 
depolymerizing enzyme in itself (Fig S1b), which led us to propose the hypothesis of the 
existence of a TBCB partner that would be implicated in the TBCB microtubule 
depolymerization mechanism. Specifically, we proposed that TBCB∆3 was derepressed 
on its presumed ability to bind to a partner through which it would promote microtubule 
depolymerization. For this reason, we decided to construct an affinity column containing 
the derepressed version of TBCB. The reasoning behind the use of the derepressed TBCB 
mutant was to increase the possibility of identifying partners that would not be easy to 
discover with the wild-type repressed protein. 
Therefore, we have performed TBCB∆3 affinity binding studies by constructing an 
affinity column with this polypeptide bound to a matrix and incubating it with a soluble 
human cell protein extract. Our results show that this derepressed TBCB protein was able 
to interact with Hsp90, CCT, and EB1. Indeed, the amount of Hsp90 that appears to be 
bound to the affinity column containing TBCB∆3 was low compared with EB1 and CCT. 
Consequently, and although this interaction has a putative role, we did not continue 
studying this interaction. The same was true for CCT, although we can envisage an 
important role for the CCT-TBCB interaction in the process of CCT-mediated α-tubulin 
folding. 
Model of TBCB-mediated α-tubulin folding bound to CCT 
The establishment that CCT is one of the interactors of TBCB, as revealed by the use of 
the affinity column (Fig 5) adds new data to the model of how proper tubulin folding and 




































































found to associate with this chaperonin. The possibility of TBCB being a CCT substrate 
was excluded because TBCB interacts with CCT while binding α-tubulin [9]. This 
strongly suggests that the interaction of TBCB with CCT might contribute for the proper 
tubulin folding and dimerization. The interaction of TBCB with CCT is also supported by 
the fact that after incubation of different amounts of TBCB with purified bovine CCT, an 
extra band with a higher molecular mass than those corresponding to CCT or TBCB was 
recognized by anti-TBCB antiserum (our unpublished results). This band migrates at the 
same position as the extra band containing CCT, α-tubulin, and TBCB previously 
observed to occur in in vitro translation assays [9]. Together, these results led us to 
propose a model in which TBCB would recognize α-tubulin bound to CCT (Fig 7b). It 
has been shown in vitro and in vivo that free α- or β-tubulin will aggregate in the absence 
of a partner (the other tubulin partner or tubulin cofactors, [4,5]). Therefore, our proposed 
mechanism predicts that α-tubulin would be released from CCT bound to TBCB ensuring 
that the α-tubulin monomer would never aggregate. Later, the monomeric tubulin subunit 
would be transferred to TBCE for dimer assembly and incorporation into growing 
microtubules or would be transferred to the degradative pathway involving the 
proteasome if not properly folded [35]. 
Model of TBCB-mediated microtubule depolymerization 
Previous studies have shown that TBCB is regulated by phosphorylation being a substrate 
of Pak1 as revealed in a yeast two-hybrid screen. Pak1 directly phosphorylates TBCB, 
and both proteins colocalize on newly polymerized microtubules [13]. We have also 
shown that the YFP:TBCB protein colocalizes with microtubules of the mitotic spindle, 
and as mitosis progresses, the staining gradually increases in microtubules of the spindle 
midzone where active polymerizing microtubules are present. Moreover, TBCB depletion 
in neuronal cells by siRNA induces axonal extension and growth cone detachment 
suggesting a role for TBCB at microtubule tips [33]. Recently, TBCB was identified as a 
target for nitrogen-containing bisphosphonates (N-BP), drugs extensively used in the 
treatment of bone diseases. In fact, TBCB is upregulated in mammalian cells after N-BP 
treatment inducing the loss of microtubule architecture in sites of active microtubule 
assembly, such as neuronal protrusions [36]. This effect might be explained by the 
observation that overexpression of TBCB in growth cones leads to microtubule 
depolymerization [33]. 
EBs proteins are dimeric proteins formed by two functional domains [37]. The N-
terminal domain mediates microtubule binding, while the C-terminal domain has a coiled 
coil responsible for dimerization and an unstructured tail (Fig 7c). Several models have 
been proposed to explain EB binding to the plus end of microtubules. Crystal structures 
of the C-terminal domain of EB1 and the CAP-Gly domains of the dynactin subunit 
p150Glued led Hayashi and coworkers [38] to postulate that EB1 is autoinhibited and that 
this conformation is unhampered by binding of a CAP-Gly-containing protein (p150Glued, 
Fig 7c). Although TBCB and TBCE contain a CAP-Gly domain, these proteins were 
never described as localizing at microtubule tips as other +TIPs proteins. TBCE was also 
a good candidate for such a role, but we could not see interaction with EB1 in vitro. 




































































different structures solved (Fig 7), the mechanism by which EBs bind to microtubules 
remains unclear. Although the removal of the EB tail blocked, as predicted, binding to 
partners [39], it had no effect in vivo on microtubule plus-end accumulation. Also, 
removal of the C-terminal tail of EBs does not alter the global conformation of the 
protein [40], which does not support the model proposed by Hayashi and coworkers [38]. 
In addition, Buey and colleagues (40) suggested that the negative charge of the domain is 
responsible for the specificity of the EBs to the microtubule tip. Despite the different 
models that try to explain the preference of EB proteins for the growing microtubule plus 
end, it seems that EBs recognize an inaccessible region of tubulin in the GTP bound form 
[41]. It is thought that the binding of EBs to microtubule tips is dynamic, being 
characterized by rounds of binding and unbinding [19]. Although we detected an 
interaction of TBCB with EB1, in vivo and using our polyclonal antibodies against 
human or murine TBCB, we never found typical EB-comets. TBCB is a CAP-Gly-
containing protein, but when we performed double immunolabeling with GFP-EB1 and 
TBCB we could not colocalize TBCB to the microtubule tips that were clearly seen for 
EB1. For this reason, it was surprising to find that EB1 was one of the major interactors 
of TBCB. Thus, we decided to study the in vitro interaction of TBCB with EB1 using 
purified untagged proteins. Unexpectedly, we found no interaction under the conditions 
tested (Fig S2d). We could not rule out the possibility that specific posttranslational 
modifications in the EB1 protein were required for TBCB binding. This would not be the 
case for TBCB because the protein used in the affinity column was purified from E. coli 
and could not have posttranslational modifications. The detailed mass spectrometric 
analysis of the EB1 polypeptide showed an acetylation at alanine-2 (Fig S3a). This 
cotranslational acetylation occurrence takes place only in eukaryotes. This usual 
modification probably does not add functional diversity to the EB1 polypeptide, 
supporting the notion that TBCB and EB1 do not interact unless EB1 is derepressed. We 
isolated microtubule fragments containing different α- and β-tubulin polypeptides (Fig 
S4b) bound to TBCB. In our experiments ([9] and this work), TBCB did not interact 
along the microtubule, although we cannot rule out an interaction with microtubule ends. 
That we could isolate microtubule fragments with bound EB1 provided us with strong 
evidence that TBCB∆3 binds and sequesters EB1 from microtubule ends leading to 
microtubule depolymerization [42]. 
We have established that the C-terminal peptide of TBCB is required for binding to 
TBCE and for efficient tubulin heterodimer dissociation (Fig 2). TBCB also recognizes 
EB1 at the plus end of the microtubule, and our results suggest that this interaction takes 
place when EB1 is also derepressed, probably after interaction with another +TIP protein 
or after binding to microtubules. 
Finally, we have also demonstrated that cotransfection with EB1 prevents TBCB∆3 
microtubule destruction and that cells recover their normal phenotype, confirming that 
TBCB∆3 and EB1 interact in vivo. This is more than sufficient to justify microtubule 
destabilization, but, as TBCB forms an active heterodimer with TBCE in tubulin 
dissociation, we suggest that this is also the mechanism by which these proteins regulate 
microtubule dynamics (Fig 7c). 
In this way, TBCB participates in microtubule dynamics, and as shown here, the 
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Legends to figures 
 
Figure 1. TBCB is an autoinhibitory protein 
a) Schematic drawing of human TBCB depicting the three characterized (UBL, coiled-
coil and CAP-Gly) domains. The UBL domain (green) corresponds to PDB ID, 1V6E 
(UBL of murine TBCB), and the CAP-Gly domain (blue) to PDB ID, 1TOV (CAP-Gly 
domain of F53f4.3, [26]. In light blue are the corresponding residues that form the 
conserved groove in p150Glued, interacting with the C-terminal peptide of α-tubulin [30, 
31]. The last nine residues, which are present in the solved domain of F53f4.3, are shown 
in red. All structures were drawn using Pymol software (http://www.pymol.org). 
b) Confocal microscopy projection image of TBCB∆3 overexpression on HeLa cells. 
TBCB∆3 (green) produces conspicuous microtubule destruction (white arrow). Moderate 
TBCB∆3 levels also severely affect the microtubule cytoskeleton. A high cytoplasmic 
tubulin background is observed in these two cells. 
c) Statistical analysis of the percentages of cells containing normal, abnormal or absent 
microtubules in TBCE, TBCB, and TBCB∆3 overexpressing HeLa cells. A highly 
significant increase in cells containing a completely destroyed microtubular cytoskeleton 
is observed when the TBCB∆3 mutant (asterisk) is overexpressed compared with wild-
type TBCB. See also Figure S1. 
 
Figure 2. Biochemical studies of TBCB∆3 
a) TBCB∆3, in contrast to complete TBCB, does not form a binary complex with TBCE. 
Plots of A280 absorbance against elution volume from the size-exclusion chromatography 
experiments. The elution profiles of TBCB, TBCB∆3, TBCE, and the interaction of these 
proteins were analyzed by gel filtration through a Superdex 200 PC 3.2/30 column (GE-
Healthcare). Three plots are shown: TBCB and TBCB∆3 alone (blue), TBCE alone (red), 




































































subjected to SDS-PAGE. The final concentrations used were 18 µM for TBCE and 15 
µM for TBCB and TBCB∆3. 
b) and c) Nonclassical two-dimensional native SDS-PAGE of complexes formed in 
tubulin dissociation experiments. Aliquots of TBCB (b) or TBCB∆3 (c) and TBCE and 
tubulin heterodimers were incubated at 30°C for 30 min and loaded onto a 6% native 
minigel (1D). C, control of tubulin heterodimers;  C1, TBCB∆3; C2, tubulin dissociation 
in the presence of TBCE and TBCB∆3 for 30 min. Bands containing this first dimension 
were excised from the gel and loaded onto an 8.5% SDS-polyacrylamide gel as described 
in Experimental procedures (2D). After electrophoresis, the gels were stained with 
Coomassie Blue. The second dimension (2D) shows the molecular compositions of the 
ternary complex in panel b (TBCE, TBCB, and α-tubulin) and of the binary complex 
(TBCB∆3 and α-tubulin) in panel c. 
d) TBCB and TBCB∆3 do not dissociate the tubulin heterodimer. Aliquots containing 
TBCB or TBCB∆3 were incubated at 30°C for 30 min with tubulin heterodimers in the 
presence and absence of TBCE and in the presence of TBCA. The drawing on the right 
shows the migration of the different proteins and complexes. 
e) TBCE slowly dissociates the tubulin heterodimer. Time-course of tubulin dissociation 
in the presence of stoichiometric amounts of TBCE. C, control of tubulin heterodimers 
incubated for 30 min. Samples were frozen in dry ice until they were loaded into the 
native gel. 
f) TBCE/TBCB, the tubulin dimer dissociation machine. Time-course of tubulin 
dissociation in the presence of TBCE and stoichiometric amounts of TBCB or TBCB∆3. 
C1, TBCB; C2, TBCB∆3; C3, control of tubulin heterodimers; C4, tubulin dissociation in 
the presence of TBCE for 30 min. After times indicated, samples were frozen on dry ice 
until they were loaded into the native gel. The drawing on the right shows the migration 
of the different proteins and complexes. Final concentrations used were 3 µM for tubulin, 
2.5 µM for TBCE, and 2.5 µM for TBCB and TBCB∆3. 
g) Quantification of tubulin dissociation by TBCE/TBCB and TBCE/TBCB∆3. 
Quantification of the proportions of tubulin dissociation in the experiment shown in e and 
f (time 0) using ImageJ software. Data were analyzed using SigmaPlot software. 
Experiments were performed in triplicate, and the graph reports the mean ± the standard 
deviation. 
 
Figure 3. Biophysical studies of TBCB and TBCB∆3 
a) Cross-linking of TBCB and TBCB∆3 with glutaraldehyde. TBCB at 1 µM and 
TBCB∆3 at 1.5 µM were analyzed in SDS-PAGE in the presence and absence of 
glutaraldehyde (at 0.05%). EB1 at 1.5 µM was used as control (dimeric protein). 
b) Analytical ultracentrifugation of TBCB. Sedimentation velocity experiments 
performed at 160,000 × g and 20°C were analyzed to yield an estimated molecular mass 
of 25.5 kDa, in agreement with the molecular mass of the theoretical monomer (27 kDa). 





































































Figure 4. YFP:TBCB is associated to the centrosome and mitotic 
microtubules 
A) Confocal microscopy image of YFP:TBCB localization in interphase (top, left) and 
mitotic HeLa cells. YFP:TBCB is mostly cytoplasmic and concentrates at the 
centrosomes of interphase and prophase HeLa cells (top, center, arrows). In anaphase A, 
YFP:TBCB is clearly associated with spindle microtubules, also decorating microtubules 
bridging the midzone (bottom left, arrow). A midbody localization pattern is more 
obvious during anaphase B and telophase (bottom images, arrow), where there is no 
longer a centrosomal signal. 
B) Relationship of the YFP:TBCB signal with respect to the primary cilium in G1 (left) 
and G2 HeLa cells (right). Glutamylated tubulin labeling the primary cilium is 
recognized by the GT335 antibody (red). 
 
 
Figure 5. Microtubules bound EB1, Hsp90, and CCT are interactors of 
TBCB 
a) Search for TBCB partners using affinity chromatography. Purified TBCB∆3 was 
purified and coupled specifically to a Hi-Trap NHS-activated HP column (GE-
Healthcare). Human HEK293 protein extract (1 mL at 18 mg/ml) was applied to the 
column. Bound proteins were eluted using an NaCl gradient (red line). Absorbance 
intensity at 280 nm (Y-axis) is plotted against the collected volume (X-axis). 
b) SDS-PAGE analysis of the fractions eluted from the NHS column. Lane 1: Molecular 
mass marker; lane 2: aliquot of the cell extract (Control); Lane 3: FT, unbound proteins 
eluted in the void volume (flow-through); lanes 4–15: fractions eluted with 100–200 mM 
of NaCl. 
 
Figure 6. EB1 prevents TBCB∆3 microtubule destruction. 
a) Triple-labeled confocal microscopy projection images of TBCB∆3 overexpression on 
HeLa cells. TBCB∆3 (green) produces conspicuous microtubule destruction (filled 
arrow). Moderate TBCB∆3 levels also severely affect the microtubule cytoskeleton 
(empty arrow). 
b) Statistical analysis of the proportions of cells containing normal, abnormal, or absent 
microtubules in TBCE, TBCB, and TBCB∆3 overexpressing HeLa cells 24 and 48 hours 
after transfection. A highly significant increase in cells containing a completely destroyed 
microtubular cytoskeleton is observed when the TBCB∆3 mutant is overexpressed 
compared with the wild-type construct. See also Figures S3 and S4. 
 
Figure 7. Models of TBCB auto-inhibition, interaction with CCT and with 
EB1 at the microtubule end 
(a) The C-terminal region of TBCB functions as an autoinhibitory peptide when bound to 
the CAP-Gly domain of the protein. 
The three domains of TBCB are depicted. The N-terminus contains the UBL (Fig 1, PDB 




































































terminal domain contains the CAP-Gly domain (PDB ID, 1V6E, blue/purple).The acidic 
tail of CAP-Gly domain is shown in red and orange. We propose that the C-terminal tail 
of TBCB is responsible for the autoinhibition of the protein (red peptide) through the 
interaction with the CAP-Gly domain (blue), specifically with the highly conserved 
hydrophobic cavity present in the CAP-Gly domain (light blue). In contrast, if the C-
terminus region does not interact with the CAP-Gly domain (orange peptide), the protein 
is derepressed. The hypothetical models of TBCB∆3 and TBCB∆9 showing the structure 
of the protein lacking the last three or nine amino acids are shown. 
b) Model of TBCB-mediated α-tubulin folding bound to CCT. In a first step, prefolding 
transfers α-tubulin polypeptides (yellow) to CCT (PDB ID, 2XSM, grey) [34]. After the 
binary complex is formed with CCT, the α-tubulin, which is in quasi-native state, 
interacts with TBCB that would be attached to the chaperonin to follow quickly with the 
postchaperonin folding pathway necessary for the incorporation of properly folded 
tubulin dimer (αβ tubulin) to the microtubule avoiding the transit of the monomer 
through the cytoplasm or degradation by the proteasome pathway [35]. 
c) Model of TBCB-mediated microtubule dynamics. Microtubules polymerize by 
addition of GTP-tubulin dimers (PDB ID, 1TUB, yellow/blue). After they are 
incorporated into the microtubule, the GTP bound to the β-tubulin subunit is hydrolyzed 
to GDP (yellow/light blue). EB1 (orange) is an intrinsic +TIP protein that specifically 
decorates growing microtubule plus ends. EB1 can bind to other +TIP proteins, such as 
CLIP-170 and p150Glued, through a CAP-Gly domain (PDB ID, 2HL5, pink) and may 
displace its theoretical C-terminal inhibitory tail. Although EBs show an elongated 
conformation in solution [40], TBCB does not interact with EB1 in vitro supporting an 
autoinhibition model similar to that proposed by Hayashi and coworkers in 2005 [38]. In 
any case, the elongated EB1 protein would bind specifically to the microtubule tip and 
not the lattice  [40], and the C-terminal tail would be oriented away from the MT tip or 
masked by a CAP-Gly-containing protein. The motif DEI/M-COO– present in TBCB is 
responsible for its autoinhibition but when derepressed induces microtubule 
depolymerization. Once EB1 is on the microtubule, it would be recognized by TBCB 
inducing EB1 detachment. In addition, TBCB might be the target for TBCE, inducing 
tubulin dimer dissociation. As a result of these interactions, microtubules would be 




































































Click here to download high resolution image
Figure 2
Click here to download high resolution image
Figure 3
Click here to download high resolution image
Figure 4
Click here to download high resolution image
Figure 5
Click here to download high resolution image
Figure 6
Click here to download high resolution image
Figure 7
Click here to download high resolution image
Table 1. Determination of the equilibrium dissociation constants for the binding of the 
fluorescein labeled TBCB and α-tubulin peptides to TBCB, TBCB∆3, and TBCB∆9 by 
fluorescence polarization (FP). FP binding assays of TBCB with FL-peptides were 
repeated up to a protein concentration of 100 µM (FigS5). See also Figure S5. 
 
   Peptide                            Protein                   Kd, µΜ 
 EEDYGLDEI (TBCB)                 TBCB                                 12  ± 1 
         "                                        TBCB∆3                                74  ± 3 
         "                                        TBCB∆9                               79  ± 4 
EEDYGL (TBCB∆3)                   TBCB                                 71  ± 3 
        "                                         TBCB∆3                             178 ± 15 
        "                                         TBCB∆9                             249 ± 30 
GEGEEEGEEY(α1/2-tub)         TBCB                                  43 ±  2 
        "                                         TBCB∆3                             113 ±  7 
        "                                         TBCB∆9                             145 ±  9 
GEGEEEGEE(α1/2-tub∆Y)       TBCB                               140 ±  4 
        "                                         TBCB∆3                            312 ±  20 
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